Jade Biosciences, Inc. has introduced JADE201, a new therapy targeting the BAFF-R receptor with extended half-life technology to enhance B cell depletion for autoimmune diseases. The first-in-human trial for rheumatoid arthritis is set to begin in the first half of 2026. JADE201 aims to offer more durable B cell depletion with less frequent dosing compared to current therapies. The company will host a conference call and webcast today to discuss the potential of JADE201 in treating autoimmune diseases. JADE201 builds on previous clinical success and is designed to provide improved efficacy with less treatment burden.

Read more at GlobeNewswire: Jade Biosciences Announces JADE201, a Potentially